Editas Medicine, Inc. EDIT announced data from the phase I/II BRILLIANCE study evaluating its lead pipeline candidate, EDIT-101, for treating blindness due to Leber congenital amaurosis type 10 (LCA10 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果